Increlex (Mecasermin)
- Drug Name: Increlex
- Generic Name: Mecasermin
- Dosage Forms and Strengths: 10 mg per mL (40 mg per vial) multiple-dose
- Manufactured by: Ipsen Biopharmaceuticals, Inc
If you are considering the import of Increlex (Mecasermin) to India, please be aware that Increlex can be imported on the name of patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:
Required Documentation for Import:
- A valid prescription from a qualified healthcare professional.
- Diagnostic reports of the patient.
- Government-issued identification proof for the patient, as recognized by the Government of India.
The order for Increlex will be confirmed upon the receipt of the following documents:
- A valid prescription from a qualified doctor.
- An import permit, if applicable.
Increlex (Mecasermin) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.
Increlex can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Srinagar, Jammu, Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. A valid prescription from a doctor and an import permit will be required to confirm an order.
IPN (Indian Pharma Network) is dedicated to facilitating the supply of Elahere (prescription medicines) to locations within India and worldwide while adhering to relevant legal requirements.
Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.
- Blood Sugar Balance: Administer INCRELEX close to meals to manage insulin-like hypoglycemic effects.
- Allergy Alert: Inform parents and patients about the potential of anaphylaxis and advise seeking immediate medical attention if a systemic allergic reaction occurs.
- Cranial Watchtower: Recommend funduscopic examination at initiation and periodically during INCRELEX therapy.
- Tissue Guardian: Conduct regular examinations to rule out potential complications in lymphoid tissue.
- Limb Protector: One should evaluate any child with the onset of a limp or hip/knee pain for possible SCFE.
- Scoliosis Sentinel: Monitor any child with scoliosis for the progression of the spine curve.
- Malignancy Alert: Discontinue therapy if evidence of malignant neoplasia develops and seek appropriate expert medical care.
- Infant Safety Note: The use of INCRELEX in infants is not recommended due to the association of benzyl alcohol with severe adverse reactions, including death.
If you are considering the import of Increlex (Mecasermin) to India, please be aware that Increlex can be imported on the name of patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:
Required Documentation for Import:
- A valid prescription from a qualified healthcare professional.
- Diagnostic reports of the patient.
- Government-issued identification proof for the patient, as recognized by the Government of India.
The order for Increlex will be confirmed upon the receipt of the following documents:
- A valid prescription from a qualified doctor.
- An import permit, if applicable.
Increlex (Mecasermin) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.
Increlex can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Srinagar, Jammu, Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. A valid prescription from a doctor and an import permit will be required to confirm an order.
IPN (Indian Pharma Network) is dedicated to facilitating the supply of Elahere (prescription medicines) to locations within India and worldwide while adhering to relevant legal requirements.
Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.
Indian Pharma Network is proficient in sourcing Increlex (Mecasermin) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedited prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.
What is Increlex used for?
INCRELEX treats children very short for their age because their bodies do not make enough insulin-like growth factor-1 (IGF-1). Such condition is called Severe Primary IGF-1 Deficiency (SPIGFD).
What is the mechanism of Increlex?
INCRELEX Mechanism of Action: In target tissues, the type 1 IGF-1 receptor, which is homologous to the insulin receptor, is activated by IGF-1, resulting in intracellular signalling stimulating multiple processes resulting in growth stature.
What are the side effects of Increlex?
The common side effects of INCRELEX include hypoglycemia, injection site reactions, allergic reactions and enlarged tonsils. Call your child’s doctor if there are any side effects that bother them or do not go away. These are not all the possible side effects of INCRELEX.
When did the FDA approve Increlex?
It was approved by the FDA on 8/30/2005.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.